LDL cholesterol
Low-density lipoprotein cholesterol (LDL-C), often referred to as “LDL cholesterol,” is a major circulating cholesterol fraction and a central biomarker in cardiovascular medicine.
Low-density lipoprotein cholesterol (LDL-C), often referred to as “LDL cholesterol,” is a major circulating cholesterol fraction and a central biomarker in cardiovascular medicine. It is widely used to assess atherosclerotic cardiovascular disease risk, and elevated LDL-C is considered a causal and modifiable risk factor for myocardial infarction and other ischemic events. In clinical practice, LDL-C is a primary treatment target in dyslipidemia, with goal attainment used to guide lipid-lowering therapy in patients with diabetes, pre-diabetes, normoglycaemia, familial hypercholesterolemia, and established cardiovascular disease.
Biologically, LDL particles transport cholesterol in the bloodstream, and excess LDL-C contributes to cholesterol deposition in arterial walls. This makes LDL-C a key endpoint in studies of statins, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, inclisiran, bempedoic acid, antisense therapies, and emerging genome-editing or peptide-based approaches. LDL-C is also frequently interpreted alongside apolipoprotein B, non-HDL cholesterol, triglycerides, remnant cholesterol, and inflammatory markers such as hs-CRP, because these measures together better characterize residual atherosclerotic risk.
Where the papers sit
11 papers from the last 6 months study LDL cholesterol directly · updated from PubMed 11 Nov 2026
Study type 0 clinical trials · 9 observational · 1 human data · 1 unclassified
Themes one subject
Those 11 are all about one subject.
-
Lipid Management in Practice
Lipid management in practice centers on whether high-risk patients reach LDL-C goals and whether early control reduces recurrent cardiovascular events. Real-world cohorts repeatedly identify residual gaps across diabetes, ASCVD, hypertension, HIV, and familial hypercholesterolaemia, while pharmacist-led pathways and bempedoic acid represent pragmatic responses. ApoB–LDL-C discordance, remnant cholesterol, gut-barrier markers, cognition, and steatotic liver disease broaden assessment beyond LDL-C alone. The evidence is mainly observational, leaving the comparative effectiveness and long-term safety of these approaches open.
Papers
The 11 papers from the last 6 months that study LDL cholesterol directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Lipid Management in Practice (11)
- Real-world use of bempedoic acid for hypercholesterolaemia: a German multicentre, retrospective, cohort study. Lipids in health and disease · 19 Sept 2026 PMID 42763399
- Changes in LDL-C levels among primary health care patients with hypertension, coronary artery disease, and diabetes during a 36-month follow-up. Scandinavian journal of primary health care · 15 Sept 2026 PMID 42743594
- Early Low-Density Lipoprotein Cholesterol Target Attainment Is Associated With Fewer Recurrent Cardiovascular Events After Acute Myocardial Infarction: A Real-World Cohort Study. The American journal of cardiology · 3 Sept 2026 PMID 42692128
- Association between gut epithelial barrier biomarkers and LDL-cholesterol in HIV-infected individuals. Medicine · 15 Aug 2026 PMID 42601778
- Distance from low-density lipoprotein cholesterol targets across cardiovascular risk strata in people living with HIV: A multicentre cohort study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 10 Jul 2026 PMID 42431541
- Association of the Discordance Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol With Cognition. Journal of the American Heart Association · 3 Jul 2026 PMID 42396799
- Low-density lipoprotein cholesterol management and goal attainment at 1 year in patients with diabetes, pre-diabetes and normoglycaemia: results from the European, prospective, observational SANTORINI study. BMJ open · 29 Jun 2026 PMID 42373176
- Equitable lipid optimisation through a data-driven, pharmacist-led secondary prevention pathway. Open heart · 22 Jun 2026 PMID 42331567
- Discordant high remnant cholesterol with LDL-C increases the metabolic dysfunction-associated steatotic liver disease risk in patients with type 2 diabetes mellitus. BMJ open diabetes research & care · 16 Jun 2026 PMID 42303421
- Persistent gaps in management and risk factor control among patients with atherosclerotic cardiovascular disease: All of us research program. Atherosclerosis · 10 Jun 2026 PMID 42270564
- Homozygous familial hypercholesterolemia (HoFH) in Canada. Atherosclerosis · 2 Jun 2026 PMID 42229223
By study type
Observational studies and case reports (9)
- Real-world use of bempedoic acid for hypercholesterolaemia: a German multicentre, retrospective, cohort study. Lipids in health and disease · 19 Sept 2026 PMID 42763399
- Changes in LDL-C levels among primary health care patients with hypertension, coronary artery disease, and diabetes during a 36-month follow-up. Scandinavian journal of primary health care · 15 Sept 2026 PMID 42743594
- Association between gut epithelial barrier biomarkers and LDL-cholesterol in HIV-infected individuals. Medicine · 15 Aug 2026 PMID 42601778
- Distance from low-density lipoprotein cholesterol targets across cardiovascular risk strata in people living with HIV: A multicentre cohort study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 10 Jul 2026 PMID 42431541
- Association of the Discordance Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol With Cognition. Journal of the American Heart Association · 3 Jul 2026 PMID 42396799
- Low-density lipoprotein cholesterol management and goal attainment at 1 year in patients with diabetes, pre-diabetes and normoglycaemia: results from the European, prospective, observational SANTORINI study. BMJ open · 29 Jun 2026 PMID 42373176
- Equitable lipid optimisation through a data-driven, pharmacist-led secondary prevention pathway. Open heart · 22 Jun 2026 PMID 42331567
- Discordant high remnant cholesterol with LDL-C increases the metabolic dysfunction-associated steatotic liver disease risk in patients with type 2 diabetes mellitus. BMJ open diabetes research & care · 16 Jun 2026 PMID 42303421
- Homozygous familial hypercholesterolemia (HoFH) in Canada. Atherosclerosis · 2 Jun 2026 PMID 42229223
Human data, design not indexed (1)
- Persistent gaps in management and risk factor control among patients with atherosclerotic cardiovascular disease: All of us research program. Atherosclerosis · 10 Jun 2026 PMID 42270564
Unclassified: not yet indexed with MeSH (1)
- Early Low-Density Lipoprotein Cholesterol Target Attainment Is Associated With Fewer Recurrent Cardiovascular Events After Acute Myocardial Infarction: A Real-World Cohort Study. The American journal of cardiology · 3 Sept 2026 PMID 42692128
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-07-01. Last written: 2026-09-21 by GPT. Drafted by language models from published abstracts; not medical advice.